prikaz prve stranice dokumenta Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
  Preuzmi
PDF 1.69 MB
Znanstveni rad - Izvorni znanstveni rad
Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
European Journal of Immunology, 49 (2018), 2; 228-241. https://doi.org/10.1002/eji.201847611
Berhani, Orit; Glasner, Ariella; Kahlon, Shira; Duev‐Cohen, Alexandra; Yamin, Rachel; Horwitz, Elad; Enk, Jonatan; Moshel, Ofra; Varvak, Alexandar; Porgador, Angel; Jonjić, Stipan; Mandelboim, Ofer

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Berhani, O., Glasner, A., Kahlon, S., Duev‐Cohen, A., Yamin, R., Horwitz, E. ... Mandelboim, O. (2018). Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology, 49. (2), 228-241. doi: 10.1002/eji.201847611

Berhani, Orit, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology, vol. 49, br. 2, 2018, str. 228-241. https://doi.org/10.1002/eji.201847611

Berhani, Orit, Ariella Glasner, Shira Kahlon, Alexandra Duev‐Cohen, Rachel Yamin, Elad Horwitz, Jonatan Enk, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology 49, br. 2 (2018): 228-241. https://doi.org/10.1002/eji.201847611

Berhani, O., et al. (2018) 'Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research', European Journal of Immunology, 49(2), str. 228-241. doi: 10.1002/eji.201847611

Berhani O, Glasner A, Kahlon S, Duev‐Cohen A, Yamin R, Horwitz E, i sur.. Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology [Internet]. 17.12.2018. [pristupljeno 15.05.2024.];49(2):228-241. doi: 10.1002/eji.201847611

O. Berhani, et al., "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research", European Journal of Immunology, vol. 49, br. 2, str. 228-241, Prosinac 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:846941. [Citirano: 15.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:846941
Podaci o radu
Naslov (engleski)Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
AutorOrit Berhani
AutorAriella Glasner
AutorShira Kahlon
AutorAlexandra Duev‐Cohen
AutorRachel Yamin
AutorElad Horwitz
AutorJonatan Enk
AutorOfra Moshel
AutorAlexandar Varvak
AutorAngel Porgador
AutorStipan Jonjić
AutorOfer Mandelboim
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za histologiju i embriologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Natural killer (NK) cells are innate lymphocytes that efficiently eliminate cancerous and infected cells. NKp46 is an important NK activating receptor shown to participate in recognition and activation of NK cells against pathogens, tumor cells, virally infected cells, and self-cells in autoimmune conditions, including type I and II diabetes. However, some of the NKp46 ligands are unknown and therefore investigating human NKp46 activity and its critical role in NK cell biology is problematic. We developed a unique anti-human NKp46 monocloncal antibody, denoted hNKp46.02 (02). The 02 mAb can induce receptor internalization and degradation. By binding to a unique epitope on a particular domain of NKp46, 02 lead NKp46 to lysosomal degradation. This downregulation therefore enables the investigation of all NKp46 activities. Indeed, using the 02 mAb we determined NK cell targets which are critically dependent on NKp46 activity, including certain tumor cells lines and human pancreatic beta cells. Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Immunology
Brojčani podacivol. 49, br. 2, str. 228-241
p-ISSN0014-2980
e-ISSN1521-4141
DOIhttps://doi.org/10.1002/eji.201847611
URN:NBNurn:nbn:hr:184:846941
Datum objave publikacije2018-12-17
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1002/eji.201847611
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-02-21 17:12:07